医学
维生素D缺乏
维生素D与神经学
内科学
血脂异常
单变量分析
多元分析
多发性骨髓瘤
双膦酸盐
儿科
疾病
骨质疏松症
作者
Rahul Gujarathi,Manisha Lakhanpal,Nikhila Chelikam,Divesh Manjani,Simmy Lahori,Sai Anusha Akella,Prashanth Gumpu Shivashankar,Francis Vino Dominic Savio,Abdirazak Ibrahim Ali,Navyatha Annareddy,Aryak Singh,Lokesh Manjani,Prasanthi Vanga,Avinash Adiga
出处
期刊:Journal of Investigative Medicine
[BMJ]
日期:2024-06-16
标识
DOI:10.1177/10815589241249998
摘要
Multiple myeloma (MM), constituting 10% of hematological malignancies, poses significant morbidity and mortality, especially with skeletal involvement. Bisphosphonate use in MM may lead to severe hypocalcemia due to vitamin D deficiency (VDD), exacerbating bone-marrow plasma cell burden. We aimed to assess VDD prevalence and its impact on outcomes in MM patients. A retrospective cross-sectional analysis (2008–2018) of nationwide inpatient data identified adult MM hospitalizations with VDD using ICD-10-CM codes. Univariate and multivariate analyses were conducted to evaluate prevalence, demographics, and outcomes, with significance set at p < 0.05. Among 330,175 MM hospitalizations, 3.48% had VDD. VDD was more prevalent among 50–75 year olds (61.72% vs 59.74%), females (53.36% vs 44.34%), Blacks (23.34% vs 22.94%), Whites (65.84% vs 65.79%), higher income brackets (26.13% vs 23.85%), and those with comorbidities like hypertension (71.12% vs 69.89%), dyslipidemia (42.47% vs 34.98%), obesity (13.63% vs 10.19%), and alcohol abuse (1.61% vs 1.34%). In regression analysis, VDD in MM patients correlated with higher morbidity (adjusted odds ratio (aOR): 1.24, 95% confidence interval (95% CI): 1.14–1.36) and major disability (aOR: 1.26, 95% CI: 1.20–1.30). MM patients with VDD exhibit worse outcomes, underscoring the importance of recognizing and managing VDD promptly. Further prospective studies are needed to validate our findings and explore the impact of vitamin D supplementation on MM patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI